FDA Mulls “Fast Track” Approach For Priority Review Voucher Eligibility
Executive Summary
FDA should consider setting up a process to pre-determine whether a product being developed for a neglected tropical disease will qualify for a priority review voucher, BIO Ventures for Global Health VP-Strategy & Operations Wendy Taylor said Dec. 12 at a public hearing convened by the agency